BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15318247)

  • 1. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival.
    Lamba R; Abella E; Kukuruga D; Klein J; Savasan S; Abidi MH; Mohamed A; Peres E
    Leukemia; 2004 Oct; 18(10):1681-6. PubMed ID: 15318247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
    Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
    Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
    Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
    Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study.
    Choi SJ; Lee KH; Lee JH; Kim S; Chung HJ; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Aug; 26(3):327-32. PubMed ID: 10967574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
    Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms.
    Suttorp M; Schmitz N; Dreger P; Schaub J; Löffler H
    Leukemia; 1993 May; 7(5):679-87. PubMed ID: 8097800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
    Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
    Huisman C; de Weger RA; de Vries L; Tilanus MG; Verdonck LF
    Bone Marrow Transplant; 2007 Mar; 39(5):285-91. PubMed ID: 17262061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the method of chimerism monitoring after allogeneic stem cell transplantation using multiplex polymerase chain reaction amplification of short tandem repeat markers and Amelogenin.
    Sufliarska S; Minarik G; Horakova J; Bodova I; Bojtarova E; Czako B; Mistrik M; Drgona L; Demitrovicova M; Lakota J; Krivosikova M; Kovacs L
    Neoplasma; 2007; 54(5):424-30. PubMed ID: 17688372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic stem cell transplantation].
    Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
    Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):208-11. PubMed ID: 12812663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of mixed hematopoietic chimerism in pediatric patients with leukemia after allogeneic stem cell transplantation by quantitative PCR analysis of variable number of tandem repeat and testis determination gene.
    Wang LJ; Chou P; Gonzalez-Ryan L; Huang W; Haut PR; Kletzel M
    Bone Marrow Transplant; 2002 Jan; 29(1):51-6. PubMed ID: 11840144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative chimerism kinetics in relapsed leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Qin XY; Li GX; Qin YZ; Wang Y; Wang FR; Liu DH; Xu LP; Chen H; Han W; Wang JZ; Zhang XH; Li JL; Li LD; Liu KY; Huang XJ
    Chin Med J (Engl); 2012 Jun; 125(11):1952-9. PubMed ID: 22884060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
    Bader P; Kreyenberg H; Hoelle W; Dueckers G; Handgretinger R; Lang P; Kremens B; Dilloo D; Sykora KW; Schrappe M; Niemeyer C; Von Stackelberg A; Gruhn B; Henze G; Greil J; Niethammer D; Dietz K; Beck JF; Klingebiel T
    J Clin Oncol; 2004 May; 22(9):1696-705. PubMed ID: 15117992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of chimerism in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
    Furukawa T; Hashimoto S; Inano K; Yamazaki F; Takeda H; Kakihara T; Yano T; Abe T; Higuchi W; Toba K; Takahashi M; Koike T; Aizawa Y
    Rinsho Ketsueki; 2001 Jun; 42(6):488-95. PubMed ID: 11505528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation.
    Antin JH; Childs R; Filipovich AH; Giralt S; Mackinnon S; Spitzer T; Weisdorf D
    Biol Blood Marrow Transplant; 2001; 7(9):473-85. PubMed ID: 11669214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.